Literature DB >> 15731064

Interactions of OspA monoclonal antibody C3.78 with Borrelia burgdorferi within ticks.

Clay L Gipson1, Aravinda M de Silva.   

Abstract

The Borrelia burgdorferi outer surface protein A (OspA) vaccine induces antibodies that prevent transmission from the tick to the host. Here we describe studies with an OspA monoclonal antibody (C3.78) to understand the mechanism by which antibodies entering the tick block Borrelia transmission. Host complement in the tick's blood meal did not contribute to protection because the antibody was equally effective whether infected ticks fed on normal or complement-deficient mice. Antibody-mediated cross-linking of bacteria or cross-linking of OspA molecules was not required for protection because C3.78 Fab' fragments were as effective as whole antibody molecules. At low C3.78 concentrations, transmission was blocked despite the presence of many live spirochetes within the tick, confirming that clearance of Borrelia organisms was not required to block transmission. We propose that OspA antibody binding to the surface of spirochetes blocks transmission by a mechanism that does not require bacterial killing.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15731064      PMCID: PMC1064931          DOI: 10.1128/IAI.73.3.1644-1647.2005

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  18 in total

1.  Complement-mediated killing of the Lyme disease spirochete Borrelia burgdorferi. Role of antibody in formation of an effective membrane attack complex.

Authors:  S K Kochi; R C Johnson; A P Dalmasso
Journal:  J Immunol       Date:  1991-06-01       Impact factor: 5.422

2.  Influence of outer surface protein A antibody on Borrelia burgdorferi within feeding ticks.

Authors:  A M de Silva; N S Zeidner; Y Zhang; M C Dolan; J Piesman; E Fikrig
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

3.  Molecular mapping of Osp-A mediated immunity against Borrelia burgdorferi, the agent of Lyme disease.

Authors:  J E Sears; E Fikrig; T Y Nakagawa; K Deponte; N Marcantonio; F S Kantor; R A Flavell
Journal:  J Immunol       Date:  1991-09-15       Impact factor: 5.422

4.  Characterization of the physiological requirements for the bactericidal effects of a monoclonal antibody to OspB of Borrelia burgdorferi by confocal microscopy.

Authors:  R Escudero; M L Halluska; P B Backenson; J L Coleman; J L Benach
Journal:  Infect Immun       Date:  1997-05       Impact factor: 3.441

Review 5.  Lyme borreliosis.

Authors:  R B Nadelman; G P Wormser
Journal:  Lancet       Date:  1998-08-15       Impact factor: 79.321

6.  Immunization of mice by recombinant OspA preparations and protection against Borrelia burgdorferi infection induced by Ixodes ricinus tick bites.

Authors:  L Gern; O Rais; C Capiau; P Hauser; Y Lobet; E Simoen; P Voet; J Pêtre
Journal:  Immunol Lett       Date:  1994-03       Impact factor: 3.685

7.  Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity.

Authors:  M R Wessels; P Butko; M Ma; H B Warren; A L Lage; M C Carroll
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-05       Impact factor: 11.205

8.  Borrelia burgdorferi infection and immunity in mice deficient in the fifth component of complement.

Authors:  L K Bockenstedt; S Barthold; K Deponte; N Marcantonio; F S Kantor
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

9.  Facilitation of complement-dependent killing of the Lyme disease spirochete, Borrelia burgdorferi, by specific immunoglobulin G Fab antibody fragments.

Authors:  S K Kochi; R C Johnson; A P Dalmasso
Journal:  Infect Immun       Date:  1993-06       Impact factor: 3.441

10.  Borrelia burgdorferi OspA is an arthropod-specific transmission-blocking Lyme disease vaccine.

Authors:  A M de Silva; S R Telford; L R Brunet; S W Barthold; E Fikrig
Journal:  J Exp Med       Date:  1996-01-01       Impact factor: 14.307

View more
  7 in total

1.  Broadly Protective Multivalent OspA Vaccine against Lyme Borreliosis, Developed Based on Surface Shaping of the C-Terminal Fragment.

Authors:  Abhijeet Nayak; Wolfgang Schüler; Stefan Seidel; Ivan Gomez; Andreas Meinke; Pär Comstedt; Urban Lundberg
Journal:  Infect Immun       Date:  2020-03-23       Impact factor: 3.441

2.  Agglutination of Borreliella burgdorferi by Transmission-Blocking OspA Monoclonal Antibodies and Monovalent Fab Fragments.

Authors:  Amber M Frye; Monir Ejemel; Lisa Cavacini; Yang Wang; Michael J Rudolph; Renjie Song; Nicholas J Mantis
Journal:  Infect Immun       Date:  2022-08-24       Impact factor: 3.609

3.  Reciprocal expression of ospA and ospC in single cells of Borrelia burgdorferi.

Authors:  Siddharth Y Srivastava; Aravinda M de Silva
Journal:  J Bacteriol       Date:  2008-03-21       Impact factor: 3.490

4.  Design and development of a novel vaccine for protection against Lyme borreliosis.

Authors:  Pär Comstedt; Markus Hanner; Wolfgang Schüler; Andreas Meinke; Urban Lundberg
Journal:  PLoS One       Date:  2014-11-19       Impact factor: 3.240

Review 5.  Vector microbiota manipulation by host antibodies: the forgotten strategy to develop transmission-blocking vaccines.

Authors:  Apolline Maitre; Alejandra Wu-Chuang; Justė Aželytė; Vaidas Palinauskas; Lourdes Mateos-Hernández; Dasiel Obregon; Adnan Hodžić; Claire Valiente Moro; Agustín Estrada-Peña; Jean-Christophe Paoli; Alessandra Falchi; Alejandro Cabezas-Cruz
Journal:  Parasit Vectors       Date:  2022-01-04       Impact factor: 3.876

Review 6.  The year that shaped the outcome of the OspA vaccine for human Lyme disease.

Authors:  Raymond J Dattwyler; Maria Gomes-Solecki
Journal:  NPJ Vaccines       Date:  2022-01-27       Impact factor: 9.399

7.  Vaccination against Lyme disease: Are we ready for it?

Authors:  Patricia Kaaijk; Willem Luytjes
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.